Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Urogenital Neoplasms × anlotinib × 1 year × Clear all

Sponsor

Conditions

Small Cell Lung Carcinoma 6 Carcinoma, Non-Small-Cell Lung 5 Thyroid Neoplasms 3 Sarcoma 3 Pancreatic Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Whole-Brain Radiotherapy 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Platinum-resistant Ovarian Cancer (PROC) 1 Lung Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Extensive Stage Lung Small Cell Cancer 1 Craniopharyngioma 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

pembrolizumab 3 Nivolumab 3 Ipilimumab 3 vedolizumab 2 fludarabine 2 darolutamide 2 cabozantinib 2 atezolizumab 2 aldesleukin 2 Specimen Handling 2 Riluzole 2 Prednisone 2 Magnetic Resonance Spectroscopy 2 LDP-02 2 Infliximab 2 Immunoglobulin G 2 Fecal Microbiota Transplantation 2 Disulfides 2 Cyclophosphamide 2 CTLA-4 Antigen 2 CT-P13 2 Biopsy 2 prednylidene 1 olaparib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 deltacortene 1 abiraterone 1 abemaciclib 1 Watchful Waiting 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡